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 Pathophysiology of Rosacea 
 Rosacea is a common chronic, often underdiagnosed, 
skin disease of uncertain etiology. The various clinical 
manifestations associated with this disease most fre-
quently occur in the light-skinned Caucasian population, 
and in persons between 30 and 50 years of age  [1, 2] . Un-
til now the conventional wisdom has been that rosacea is 
more common in women than in men  [2] , whereas a re-
cent analysis based on a cross-sectional study of rosacea 
(1995–2002) in 50,235 outpatients indicates that overall 
both sexes are equally affected by the disease  [3] . The der-
matological condition of rosacea mainly affects the cheek, 
nose, chin and central forehead. Furthermore, the dis-
ease may be linked to ocular manifestations  [4] . The ear-
liest symptoms associated with rosacea are intermittent, 
central facial flushing and erythema. More than 90% of 
the patients with rosacea experience flushing with epi-
sodes lasting up to 30 min occurring daily in more than 
60% of the affected individuals  [5–7] . With repetitive cy-
cles, flushing becomes more prominent and facial red-
ness deepens, in the end repeated episodes of facial flush-
ing may cause persistent erythema and telangiectasia  [8] . 
Many patients suffer from a stinging pain associated with 
episodes of flushing which can appear unpredictably or 
in relation to environmental, chemical, food or emotion-
al triggers, especially exposure to sun  [1] .
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 Abstract 
 Until today, the pathogenesis of rosacea is not known in de-
tail. Yet in recent years evidence has been accumulating that 
rosacea with its common symptoms such as inflammatory 
lesions, erythema, telangiectasia, phymatous changes, and 
ocular symptoms is of inflammatory nature. Tetracycline de-
rivatives like doxycycline successfully used in the treatment 
of skin diseases like acne and rosacea seem to inhibit differ-
ent inflammatory pathways involved in the pathogenesis by 
various modes of action. Although data for skin diseases are 
relatively scanty, the following modes of action of tetracy-
clines seem to be most relevant for an effective treatment of 
acne and rosacea: inhibition of matrix metalloproteinases, 
downmodulation of cytokines, inhibition of cell movement 
and proliferation, inhibition of granuloma formation, inhibi-
tion of reactive oxygen species, nitric oxide, and angiogen-
esis, whereas inhibition of phospholipase A2 seems to be of 
lower importance. The role of the saprophytic mite  Demodex 
folliculorum remains to be clarified. Additional studies are 
necessary to further elucidate how tetracyclines work in ro-
sacea treatment.  Copyright © 2009 S. Karger AG, Basel 
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 Until today, the pathogenesis of rosacea is not known 
in detail. Yet in recent years evidence has been accumu-
lating that rosacea is of inflammatory nature even 
though most data have their origin in diseases related to 
rosacea, namely acne vulgaris and, most commonly, 
periodontitis. For example, in biopsies of inflammatory 
lesions from patients with acne an increase in proin-
flammatory cytokines like tumor necrosis factor-  
(TNF-  ) and interleukin-1  (IL-1  ) could be demon-
strated  [9] . These cytokines trigger a chain of reactions, 
such as the release of matrix metalloproteinases (MMPs), 
especially MMP-1, -3 and -9, involved in the degrada-
tion of extracellular matrix and inflammatory damage 
in turn supporting the development of papulopustular 
lesions  [10, 11] . The fact that such lesions occur in rosa-
cea as well supports the thesis of an inflammatory 
pathophysiology of this disease. Anyway, 2 further me-
diators of inflammation, reactive oxygen species (ROS) 
and nitric oxide (NO), have been shown to play a role in 
rosacea pathophysiology  [12, 13] . It has in particular 
been shown that patients with severe rosacea have an 
impaired defense capacity against the proinflammatory 
and damaging effects of ROS  [11, 14] . Reactive nitrogen 
intermediates like NO in turn are responsible for vaso-
dilatation possibly leading to increased vessel permea-
bility and edema and supporting erythema and telangi-
ectasia  [11] . Flushing is caused by increased cutaneous 
blood flow because of capillary dilatations and is be-
lieved to be under vasomotor control  [8] . It seems to 
arise from a dysregulation in the cutaneous vasomotor 
response, which, triggered by neurogenic, hormonal, 
thermal, topical or other stimuli, leads to an abnormal 
and persistent dilatation of blood vessels  [15] . It is worth 
discussing that flushing – at least in the erythematotel-
angiectatic subtype of rosacea – may be due in part to 
an abnormal expression, function, distribution or re-
sponsiveness of   -adrenergic receptors  [15] .
 A possible link between  Helicobacter pylori infections 
and rosacea is discussed in the literature as well  [11] . Sev-
eral authors have also proposed that microscopic sapro-
phytic mites – known as  Demodex folliculorum – play a 
pathogenic role in papulopustular rosacea  [16–21] . Mites 
increased in number may be involved in the pathogenesis 
of rosacea by provoking inflammatory or allergic reac-
tions, by mechanical blockage of follicles or by acting as 
vectors for micro-organisms  [17, 22] . It has been suggest-
ed that a density of  D. folliculorum  1 5/cm 2 as determined 
with the standardized skin surface biopsy could be re-
garded as pathogenic  [18] , but other observations suggest 
that increased density of  D. folliculorum , at least in peri-
oral dermatitis, is a secondary phenomenon, associated 
with previous treatment with topical steroids  [23] .
 Most recently it could be shown that symptoms of ro-
sacea are exacerbated by factors that trigger innate im-
mune responses, such as the release of cathelicidin anti-
microbial peptides. These peptides are produced and se-
creted by keratinocytes  [24] . Clearly, there is a role of 
cathelicidin in skin inflammatory responses  [25] , espe-
cially for cathelicidin LL-37  [24] . Individuals with rosa-
cea express cathelicidin at abnormally high levels in their 
facial skin, and specific proteolytically processed forms 
of cathelicidin peptides found in rosacea differ from 
those in normal individuals  [25] . This means that in the 
pathogenesis of rosacea, cathelicidin peptides are abnor-
mally processed to forms that induce inflammation 
 [26] .
 If changes in the skin pH play a role in pathophysiol-
ogy, as it is reported for several skin diseases like irritant 
contact dermatitis, atopic dermatitis, ichthyosis or acne 
vulgaris  [27] , remains to be clarified.
 In summary, there is good evidence that all the stig-
mata of rosacea are manifestations of an inflammatory 
process. It is  highly probable that inflammatory path-
ways involved in the pathogenesis of this disease con-
comitantly contribute to the common complaints such as 
inflammatory lesions sensu stricto, erythema, telangiec-
tasia, phymatous changes and ocular symptoms  [28] . 
This view is supported by the fact that drugs like doxycy-
cline successfully used in the treatment of rosacea inhib-
it various pathways of inflammation finally leading to an 
improvement of symptoms  [9, 13, 29–31] . Furthermore, 
the anti-inflammatory properties of doxycycline strong-
ly correspond to the pathophysiologic inflammatory 
mechanisms related to rosacea  [31] .
 Tetracyclines and Their Role in the Treatment of 
Rosacea 
 Tetracyclines are broad-spectrum antibiotics that have 
been used in the treatment of rosacea for decades  [9] . 
Treatment of papulopustular rosacea with tetracycline 
requires a 3- or 4-week regimen to achieve substantial 
improvement  [32] . Tetracycline (250–1,000 mg per day), 
doxycycline (100–200 mg per day and – as demonstrated 
recently – also 20–40 mg per day) and minocycline (50–
100 mg per day) are the most commonly applied com-
pounds  [33] . Until recently, the use of oral tetracyclines 
for rosacea was mainly based on clinical experience and 
a limited number of placebo-controlled studies  [9, 34, 35] . 
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However, most recent studies were carried out on the ba-
sis of a sufficiently large number of patients and can 
therefore be considered to be of high quality  [31] .
 Today, the effectiveness of tetracyclines in skin dis-
eases is considered to depend on their nonantibiotic ac-
tions, though originally developed as antibacterial drugs. 
Tetracyclines, besides acting as antibiotics, may also af-
fect inflammation  [31, 36] , cell proliferation  [37] , apopto-
sis  [38, 39] and angiogenesis  [40] by variable mechanisms 
of action. In particular, it is the ability of tetracyclines to 
reduce the inflammatory response that significantly con-
tributes to the clinical effectiveness for various indica-
tions like rosacea  [30] . However, the observation that tet-
racyclines under ex vivo conditions augment the expres-
sion of cyclo-oxygenase-2 and increase prostaglandin E2 
production  [41] is not in line with the data described be-
fore because cyclo-oxygenase-2 and prostaglandin E2 ac-
tivation are known to propagate inflammatory processes 
 [42] .
 Today, second-generation tetracyclines, including mi-
nocycline and especially doxycycline, are most frequent-
ly and most successfully used in the treatment of rosacea. 
In comparison with their parent drug, the new genera-
tion of tetracyclines has an improved bioavailability, a 
longer elimination half-life and can be taken with food 
which minimizes gastrointestinal side effects  [43] . A big 
advantage over the parent drug is that these substances 
are helpful for rosacea patients already at a subantimicro-
bial yet anti-inflammatory dose  [31] . Thus, an effective 
and tolerable long-term therapy is feasible without run-
ning the risk of long-term antibiosis, i.e. undesired ad-
verse effects such as gastrointestinal distress, candidal 
vulvovaginitis and/or the development of antibiotic-re-
sistant micro-organisms  [44] .
 Subantimicrobial-dose doxycycline is the only tetra-
cycline approved in the USA for long-term use for up to 
12 months  [33] . The dosage of 20 mg of doxycycline hy-
clate twice daily or 40 mg once daily has been shown to 
be effective in the treatment of papulopustular rosacea 
with an excellent risk-benefit ratio. It has in particular 
been found that a 40-mg controlled-release formulation 
of doxycyline, applied once daily as Oracea TM , conferred 
peak anti-inflammatory efficacy in the treatment of ro-
sacea  [45] . At subantimicrobial doses, long-term use of 
anti-inflammatory-dose doxycyline might not propagate 
bacterial resistance  [33, 44, 46] . Two phase III, parallel-
group, multicenter, randomized, double-blind, placebo-
controlled studies have in fact further demonstrated the 
efficacy and safety of a 16-week treatment with anti-in-
flammatory doxycycline (40 mg once daily) in patients 
with rosacea  [31] . This medication led to a significant re-
duction in inflammatory lesions  [31] . Hence anti-inflam-
matory doxycycline (40 mg) applied once daily must be 
regarded to be a promising therapy strategy for papulo-
pustular rosacea – besides topical therapies with metro-
nidazole or azelaic acid. However, to our knowledge it is 
not known if tetracyclines, in particular doxycycline, are 
able to improve the symptom flushing, whereas topical 
application of selective   1-adrenergic receptor agonists 
like oxymetazoline seems to be successful in this regard 
 [15] . This finding is in accordance with the belief that 
flushing may be due, at least partly, to an abnormal ex-
pression, function, distribution or responsiveness of   -
adrenergic receptors  [15] .
 Tetracycline Derivatives, Especially Doxycycline, 
and Their Mode of Action 
 Inhibition of MMPs 
 In the 1980s, Golub et al.  [47] discovered a novel non-
antimicrobial property of tetracyclines. They found that 
tetracyclines have the ability to inhibit the activity of in-
terstitial MMPs from a variety of cells like neutrophils 
and macrophages and tissues such as skin  [47, 48] . MMPs 
are zinc-dependent enzymes significantly involved in the 
remodeling of connective tissue. They are secreted by res-
ident and inflammatory cells that collectively degrade 
most of the constituent macromolecules of the extracel-
lular matrix. These enzymes with their subgroups of col-
lagenases (MMP-1, MMP-8, MMP-13) and gelatinases 
(MMP-2, MMP-9) play an important role in many in-
flammatory diseases, wound healing, embryogenesis, tu-
mor invasion and angiogenesis  [30, 49] . Furthermore, 
MMPs contribute to cytokine (i.e. IL-1  )-induced vascu-
lar dysfunction as could be shown in vitro and in an in 
vivo model of acute inflammation  [50] ( fig. 1 ). Later it has 
been observed that tetracycline inhibition of MMPs dif-
fers between species, tissues and even cells from the same 
tissue  [51] . Furthermore, it could be shown that the mem-
bers of the tetracycline family differ in their potency to 
inhibit extracellular collagenase activity, with the semi-
synthetic drugs doxycycline and minocycline being more 
potent than tetracycline itself  [48, 52] .
 In vitro and in vivo studies report that tetracycline 
derivatives are able to inhibit the activity of various 
MMPs playing a role in the breakdown of the extracel-
lular matrix, including MMP-13 (collagenase-3), MMP-8 
(collagenase-2), MMP-1 (collagenase-1), MMP-2 (gela-
tinase A), MMP-9 (gelatinase B) and MMP-12 (macro-
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phage metalloelastase)  [11, 31, 53, 54] . For some MMPs it 
has been shown that, in addition to inhibiting MMP ac-
tivity, tetracycline derivatives like doxycycline may also 
reduce enzyme expression at the transcriptional level 
 [55] .
 While the inhibitory effects of low-dose doxycycline on 
MMPs are described in detail in the context of the man-
agement of periodontitis  [56–60] , available data for skin 
diseases like acne or rosacea are relatively scanty. How-
ever, there are data indicating that MMP-9 can be inhib-
ited by tetracycline derivatives as well probably due to re-
duction in the chemotaxis of neutrophils, which are known 
to store MMP-9  [30] . The inhibitory effect of doxycycline 
on MMP-9 levels could be approved by studies using an 
experimental dry-eye model in mice  [61] . The studies of 
Kim et al.  [62] showing that doxycycline inhibits the TGF-
  1-induced production of MMP-9 in cultured corneal ep-
ithelial cells as well suggest hat this finding might be rel-
evant to the pathogenesis in ocular rosacea  [49, 62] . More 
evidently, recent work even suggests that high levels of 
MMP-8 in the tear fluid are correlated with ocular rosacea 
and that low-dose doxycycline is able to lower the patho-
logically increased levels in these patients. Määtä et al.  [63] 
actually found that the mean MMP-8 concentrations were 
significantly higher in patients with ocular rosacea (157 
  g/ml) than in normal subjects (53   g/ml) but decreased 
to 79 and 53   g/ml in patients with ocular rocacea after 4 
and 8 weeks of treatment with low-dose doxycycline, re-
spectively ( fig. 2 ). The reduction in MMP-8 levels was re-
lated to a relief in the patients’ subjective symptoms  [63] . 
Up to now, doxycycline hyclate is the only drug whose 
properties to inhibit MMPs have sufficed for approval of 
clinical use  [64] , but the exact mode of action on the mo-
lecular level is still unknown. Recent work indicates that 
doxycycline does not directly inhibit MMPs or the synthe-
sis/secretion of these proteases. Though orally adminis-
tered doxycycline caused a disappearance of the MMPs 
indicative of disease progression in patients with superfi-
cial ocular diseases, especially rosacea, no doxycyline 
could be detected in their tear samples  [65] . Thus, doxycy-
cline seems to influence MMPs in an indirect way.
 Inhibition of Phospholipase A2 
 Extracellular phospholipase A2 (PLA2) plays an im-
portant role in articular and extra-articular inflamma-
tory processes  [66] . The tetracyclines minocycline and, to 
a lesser extent, doxycycline have been shown to be in-
hibitory to both pancreatic and nonpancreatic PLA2 in 
vitro  [66] . However, the doxycycline concentration need-
ed for in vitro inhibition of the enzyme activity in serum 
from patients with acute necrotizing pancreatitis is high-
er than that achieved after intravenous injections in clin-
ical use  [67] . Thus, up to now the importance of PLA2 
inhibition by doxycycline in vivo and especially in skin 
diseases like rosacea remains unclear, particularly with 
regard to the finding that in tears of patients with ocular 


























































 Fig. 1. Application of MMP inhibitor doxycycline (30   M ) abol-
ishes the spontaneous loss of phenylepinephrine-induced vascu-
lar tone of rat aortae in vitro. The response of aortic rings taken 
from normal rats to phenylepinephrine is shown. Phenylepineph-
rine was added after 1.5 h of equilibration and then rings were 
treated with doxycycline (30   M ; black circles) or double-distilled 
H 2 O (white circles) vehicle (from Lalu et al.  [50] , with permis-
sion). 
 Fig. 2. Tear fluid MMP-8 concentration in controls, as well as 
ocular rosacea (OCR) patients before treatment and after 4 and 8 
weeks of oral doxycycline regimen. Means  8 SD are presented 
(from Määtä et al.  [63] , with permission). 
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the content of PLA2 of group IIA is significantly lower 
compared to normal controls  [68] .
 Downmodulation of Cytokines 
 Inflammatory lesions from acne patients contain in-
creased levels of proinflammtory cytokines like TNF-  
and IL-1  postulated to be involved in the inflammatory 
cascade of acne  [9] and triggering chemical responses like 
the release of certain MMPs  [13] . There is evidence that 
tetracyclines at subantimicrobial doses reduce inflam-
mation by their downregulating properties  [36] , especial-
ly with respect to TNF-  and IL-1   [69] , IL-8  [70] and 
IL-10  [71] . Furthermore, low-dose doxycycline seems to 
be able to normalize lowered levels of cytokines neces-
sary for repair and regeneration. In patients with severe 
generalized chronic periodontitis, subantimicrobial-
dose doxycycline increases the levels of TGF-  1 in the 
gingival crevicular fluid and by this means contributes to 
the inhibition of connective tissue breakdown  [72] . For 
rosacea no corresponding studies are available so far, but 
it is to be assumed that the described mechanisms are, at 
least partly, transferable to this disease as well.
 Inhibition of Cell Movement and Proliferation 
 The migration of white blood cells is an early and im-
portant event in the process of inflammation. Data from 
the late 1970s and 1980s show that tetracyclines are able to 
interfere with neutrophil function  [37] , especially with 
neutrophil movement, at least in vitro  [73] . Tetracyclines 
have also been found to be able to inhibit the mitogen-in-
duced proliferative responses of human lymphocytes in 
vitro by blockage of blast formation, with doxycycline be-
ing the most potent inhibitor among 3 tested tetracycline 
analogues  [37] . Gabler et al.  [74] could show that the chela-
tion of intracellular calcium, which, as a second messen-
ger, is important for the regulation of cell movement, is 
involved in the mechanism of inhibition. Besides migra-
tion, tetracyclines are also able to inhibit neutrophil-medi-
ated superoxide anion synthesis and degranulation, i.e. 
mechanisms which may also be involved in the inflamma-
tory process  [75] . Lately, Gabler and Tsukuda  [76] found 
that doxycycline also exerts a slight inhibitory effect on 
neutrophil adherence to surfaces coated with differing 
proteins, which interestingly could only be observed at low 
drug concentrations of doxycycline, while tetracycline in-
hibited leukocyte adherence in a dose-related manner.
 Inhibition of Granuloma Formation 
 Granulomatous inflammation is a common compo-
nent of many diseases, including rosacea. Tetracyclines 
have been shown to inhibit granuloma formation of hu-
man peripheral blood mononuclear cells incubated with 
dextrin beads  [77] . In this in vitro system doxycycline 
was proven to have a 10-fold stronger inhibitory activity 
than the parent drug tetracycline. Protein kinase C may 
be involved in the described mechanism of inhibition be-
cause tetracyclines caused a dose-dependent inhibition 
of protein kinase C in the same order of relative potency 
as was found for the inhibition of granuloma formation 
 [77] .
 Inhibition of ROS 
 Evidence has been accumulating that ROS released by 
inflammatory cells such as neutrophils  [12] are involved 
in the pathogenesis of rosacea. Patients with rosacea have 
higher ROS levels than healthy controls  [78] . Further-
more, markers of the antioxidant defense system are in-
versely correlated to the clinical manifestations of rosa-
cea. This means that in patients with mild rosacea (stage 
I or II) the superoxide dismutase activity was higher than 
in healthy controls while the malondialdehyde level (a 
biomarker for oxidative stress  [79] ) did not differ from 
controls, whereas in the severe involvement group (rosa-
cea stage III) the superoxide dismutase activity was lower 
than in the control group coupled to an increased level of 
malondialdehyde  [14] . These findings suggest that in 
mild rosacea the antioxidant defense system is activated 
in order to keep the ROS levels constant. In severer dis-
ease, the capacity of the antioxidant system is exhausted, 
leading to high levels of ROS. This belief is supported by 
recent data showing a higher ferritin expression in the 
skin, higher serum peroxide levels and significantly low-
ered total antioxidative potential serum levels in patients 
with rosacea compared with healthy control subjects, in-
dicating the onset of systemic oxidative stress in patients 
with rosacea  [80] . These findings support the ‘antioxi-
dant system defect hypothesis’ in rosacea patients, i.e. a 
reduced capacity to counter the negative effects of ROS, 
thus experiencing an increased inflammatory response 
 [13, 14] . This may also explain the pathogenetic associa-
tion between rosacea and photodamage, since long-term 
sun exposure is known to cause an increased generation 
of ROS, which, in turn, subsequently activate MMPs and 
in this way trigger the inflammation pathway  [13, 31] . 
 In vitro studies suggest that tetracyclines, especially 
doxycycline, show antioxidant effects by reducing ROS 
 [30, 60] . In vitro data propose that the antioxidant effect 
of these drugs does not originate from their capability to 
directly scavenge ROS but from their influence on white 
blood cells  [81] . However, the exact mechanism of action 
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of tetracyclines towards white blood cells, especially neu-
trophils, is still unknown  [12, 82] . The tetracycline-in-
duced reduction in ROS activity seems to be linked to a 
decreased degradation of extracellular matrix associated 
with a reduced activation of pro-MMPs  [31] . Thus, the 
antioxidant activity of tetracyclines may also benefit oth-
er mechanisms of inflammation.
 Inhibition of NO 
 The overproduction of NO has been implicated in the 
pathogenesis of various inflammatory diseases  [83] . NO 
secreted by endothelial cells and keratinocytes in re-
sponse to UVA and UVB radiation  [84] is thought to in-
cite the symptoms of rosacea as well  [13] . NO seems to be 
involved in vascular changes, i.e. vasodilation, which, in 
the case of rosacea, may contribute to increased vessel 
permeability, erythema, edema and telangiectatic symp-
toms  [13] . The increase in NO in response to UVA and 
UVB irradiation  [84] again refers to the widely accepted 
relationship between sun exposure and the pathogenesis 
of rosacea.
 Tetracyclines have been shown to inhibit the expres-
sion of nitric synthases under ex vivo conditions, with 
doxycycline being at least as effective as minocycline  [83] . 
Furthermore, doxycycline has been shown to be involved 
in the posttranscriptional regulation of inducible NO 
synthetase mRNA in murine macrophages  [85] . All these 
preliminary results suggest that tetracyclines, especially 
doxycycline, may have beneficial effects in the treatment 
of inflammatory diseases where excess NO has been im-
plicated in the pathophysiology, as also seems to be the 
case with rosacea.
 Inhibition of Angiogenesis 
 Angiogenesis seems to be involved in the pathogenesis 
of rosacea  [19, 86] and to be linked to MMP activity  [36] . 
In patients with rosacea, significantly increased dermal 
expression of the potent angiogenesis factor vascular en-
dothelial growth factor in lesional versus nonlesional 
skin (88.9 vs. 55.6%, respectively) was observed. Further-
more, more microvessels were observed in lesional com-
pared to clinically nonlesional skin, and a high microves-
sel density was found to be correlated with granuloma 
formation in the skin  [19] . There was also a correlation 
between high vascular density and the presence of ocular 
manifestations  [19] .
 Up to now, no study is available showing a direct or 
indirect antiangiogenic effect of tetracyclines in the 
pathogenesis of rosacea. Yet in a mouse model, doxycy-
cline has been found active in suppressing MMP-associ-
ated central nervous system angiogenesis  [49, 87] . In this 
model, doxycycline turned out to be a potent inhibitor of 
angiogenesis induced by vascular endothelial growth fac-
tor by decreasing the cerebral MMP-9 activity. The de-
crease in MMP-9 was associated with a reduced micro-
vessel count  [87] . More recently, it has been shown that 
doxycycline attains consistent antiangiogenic effects by 
inhibiting the migration of smooth-muscle cells playing 
an important role during angiogenesis and vascular re-
modeling  [88] . There is good evidence that inhibition of 
smooth-muscle cell migration is caused by the doxycy-
cline-induced upregulation of the MMP inhibitor tissue 
inhibitor of metalloproteinase-1  [88] .
 Influence on D. folliculorum 
 The saprophytic mite  D. folliculorum may play a patho-
genic role in papulopustular rosacea  [17–21] . Increased 
density of  D. folliculorum may be involved in the patho-
genesis of rosacea by supporting inflammation, mechan-
ical blockage of follicles or by acting as vectors for micro-
organisms  [17, 22] , while other authors favour the concept 
that increased mite density is the consequence of a previ-
ous treatment with topical steroids  [23] . Up to now, to our 
knowledge no study showing a relevant direct action of 
tetracyclines on the density of  D. folliculorum is avail-
able.
 Conclusion 
 It is highly probable that rosacea is of inflammatory 
nature. Inflammatory processes involved in the patho-
genesis of the disease concomitantly contribute to
the common symptoms such as inflammatory lesions in 
the stricter sense, erythema, telangiectasia, phymatous 
changes and ocular symptoms. Evidence has been accu-
mulating that tetracycline derivatives like doxycycline 
successfully used in the treatment of rosacea inhibit in-
flammatory pathways in skin diseases like acne and ro-
sacea by various modes of action. Although data for acne 
or rosacea are relatively scanty, the following modes of 
action of tetracyclines seem to be most relevant to an
effective treatment of these skin diseases: inhibition of 
MMPs, downmodulation of cytokines, inhibition of cell 
movement and proliferation, granuloma formation, ROS, 
NO and angiogenesis, whereas inhibition of PLA2 does 
not seem to matter greatly. The role of the saprophytic 
mite  D. folliculorum remains to be clarified. Neverthe-
less, future studies will have to show how tetracyclines 
work in rosacea treatment in detail.
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